探索代谢综合征护理:阿联社区药剂师的见解 - 设置基于问卷的横截面研究
Ammar Abdulrahman Jairoun1,2, Moyad Shahwan3,4, Abeer M Al-Ghananeem5
1Health and Safety Department, Dubai Municipality, Dubai, United Arab Emirates.
Frontiers in public health
|March 4, 2026
概括
阿联的社区药剂师表现出对治疗代谢综合征 (MetS) 的良好的认识和实践. 药剂师的经验和培训显著影响着他们对预防和治疗MetS的态度和做法.
科学领域:
- 制药科学 制药科学
- 公共卫生 公共卫生
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 社区药剂师在患者护理中发挥着至关重要的作用,弥合了患者和医生之间的差距.
- 关于社区药剂师对阿联代谢综合征 (MetS) 的认识,态度和实践的数据有限.
- MetS管理需要有效的药物护理来改善患者的治疗结果.
研究的目的:
- 评估阿布扎比,迪拜和北方阿联社区药房专业人员对管理和预防MetS的态度.
- 识别影响药剂师对预防和治疗MetS方法的因素.
主要方法:
- 从2023年5月到2024年2月进行了一项横截面研究.
- 使用结构化问卷对420名社区药剂师进行了面对面的采访.
- 该问卷收集了有关人口统计,态度和 MetS 预防和管理的实践的数据.
主要成果:
- 药剂师在MetS预防和治疗方面获得了75.8%的平均态度得分和86.8%的实践得分.
- 监督药剂师和那些有超过10年的经验的人对MetS表现出更积极的态度.
- 良好的实践得分与在连锁药店工作,高级职位,更长的经验和先前的MetS培训有关.
结论:
- 阿联的社区药剂师表现出对METS管理的良好知识和实践.
- 药房环境,专业经验和专业培训是提高药剂师关于MetS的态度和做法的关键因素.
- 进一步的举措应侧重于培训和经验,以优化社区药剂师提供的MetS护理.
相关概念视频
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741